Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197248 | 0.87 | CNR1 (0.40) | MAPK14FABP4FABP5OPRL1CNR1 | |
| SCHEMBL5194034 | 0.86 | TEK (0.42) | MAPK14FABP4FABP5OPRL1KDM4E | |
| SCHEMBL5196849 | 0.81 | TEK (0.40) | MAPK14FABP4FABP5OPRL1KDM4E | |
| SCHEMBL5197130 | 0.79 | TEK (0.42) | MAPK14FABP4FABP5NPSR1TEK | |
| SCHEMBL5197719 | 0.77 | MAPK14 (0.48) | MAPK14CNR1TEK | |
| SCHEMBL5198874 | 0.77 | TEK (0.42) | MAPK14FABP4FABP5KDM4ENPSR1 | |
| SCHEMBL5197077 | 0.74 | AVPR2 (0.41) | MAPK14KDM4ENPSR1 | |
| SCHEMBL5197084 | 0.74 | TEK (0.46) | MAPK14OPRL1TEK | |
| SCHEMBL5198855 | 0.74 | TEK (0.44) | MAPK14FABP4FABP5OPRL1TEK | |
| SCHEMBL5199112 | 0.73 | NPSR1 (0.43) | MAPK14NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846389-A1 | IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082002-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | claimed |
| US-20060173048-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2006-08-03 | — | — | US | claimed |
| EP-1846389-A1 | IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082002-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173048-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173048-A1 | Imidazole derivatives | GRM2, GRM1, GRIN2C | MAPK14 2620/4885FABP4 3933/4885FABP5 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.